Keywords: 
• leukotriene receptor antagonist /
• asthma /
• anti-inflammatory /
• immune function

Abstract: Objective To analyze the effect of leukotriene receptor antagonist on anti-inflammation and immune function in asthmatic patients. Methods 86 cases of asthma patients in our hospital from August to December 2014 were taken as the research objects, they were randomly divided into the observation group with 43 cases and the control group with 43 cases, the control group was treated with conventional therapy plus Seretide, the observation group was given leukotriene receptor antagonist-montelukast based on the control group, two groups were treated for 14 d. The changes of inflammatory factors and immune function, therapeutic effect, adverse reaction were compared between the two groups after treatment. In the observation group after the treatment,the IL-6, TNF-α and CRP were lower than that in the control group, the difference was statistically significant (P<0.05). In the observation group after the treatment, CD4⁺ and CD4⁺/CD8⁺ were higher than that in the control group, CD8⁺ was lower than that in the control group, the difference was statistically significant (P<0.05). After the treatment in the observation group, the ACT score was higher than that in the control group, the total effective rate was higher than that in the control group, the difference was statistically significant (P<0.05). There was no obvious adverse reaction in the two groups. Conclusion Leukotriene antagonist (montelukast) could play an important role in improving the immune function and anti-inflammation in asthma patients, which might be an important mechanism to improve the therapeutic effect of asthma.